Glenmark Pharma up 4.2% on US FDA nod for generic spray targeting $295m market

Glenmark Pharmaceuticals shares were in demand on Thursday after the company disclosed a fresh US regulatory win in its core respiratory franchise. The stock was last traded at Rs 2,341, up 4.2% for the session, as investors reacted to news that the US Food and Drug Administration has cleared its generic version of blockbuster allergy spray Flonase.

What Glenmark announced

In an exchange filing dated August 20, 2026 (page 1), Glenmark Pharmaceuticals Limited said it has received US FDA approval for Fluticasone Propionate Nasal Spray USP, 0.05 mg/spray.

The company highlighted that its product is:

• "bioequivalent and therapeutically equivalent" to the reference listed drug Flonase Nasal Spray, 0.05 mg/spray of Haleon US Holdings LLC [NDA 020121]; and
• will be distributed in the US by Glenmark Pharmaceuticals Inc., USA (pages 1–2).

The attached media release on page 2 reiterates the same details and frames the approval as part of Glenmark’s push to deepen its respiratory portfolio in North America.

Why the stock moved: US respiratory play and a sizeable reference market

The filing itself does not contain any revenue or profit figures for Glenmark, but it does give one key datapoint that helps explain the market’s reaction: the size of the reference market.

According to IQVIA sales data cited in the press release on page 2, the Flonase Nasal Spray market – including the brand and all available therapeutic equivalents – "achieved annual sales of approximately $295.2 million*" for the 12‑month period ending June 2026.

That number appears to be the main anchor for Thursday’s buying interest. A US FDA approval that opens up access to a roughly $295.2 million market in a therapy area where Glenmark already has capabilities is materially relevant for a generics-focused company, even though the filing does not quantify what share Glenmark might capture.

The company also positions this as a strategic, not just tactical, win. Marc Kikuchi, President & Business Head, North America, is quoted on page 2 as saying the approval "marks another step in expanding our respiratory portfolio in the U.S. and builds on the strong foundation we have established in this therapeutic area." He adds that Glenmark remains committed to broadening access to "quality, affordable treatment options" for patients and healthcare providers.

For investors, that language reinforces two themes:

• Glenmark is doubling down on respiratory, one of its stated focus areas (page 3 notes its portfolio focus on respiratory, dermatology and oncology).
• The US remains a key profit pool, and each incremental approval in a branded-generic market of meaningful size can support medium‑term earnings.

The stock’s 4.2% move, which came after the filing was made public, therefore appears to reflect optimism that this approval can add to Glenmark’s US generics revenue base over time.

What the filing does and does not say

While the market is clearly treating the news as positive, it is important to note what the filing does not disclose:

• There is no guidance on potential sales, market share, or ramp‑up timelines for the Fluticasone Propionate Nasal Spray.
• The company does not provide any margin, pricing, or cost details for the product.
• There is no discussion of competitive intensity beyond the statement that the IQVIA market number includes "brand and all available therapeutic equivalents" (page 2).

The press release also clarifies that Glenmark’s product "is only approved for the indication(s) listed in Glenmark’s approved label" and that IQVIA data is available "for all approved RLD indications" (page 2). It notes that Glenmark’s product "will only be marketed for the indications listed in Glenmark’s approved label, which may be different than the approved RLD indications." This is a regulatory nuance that could influence the addressable slice of the $295.2 million market, but the filing does not quantify that impact.

In other words, the share price reaction is based on the strategic significance of the approval and the headline size of the reference market, rather than on hard earnings projections.

How it fits into Glenmark’s broader story

The "About Glenmark" section on page 3 provides the broader context investors are likely keeping in mind:

• Glenmark describes itself as a "global, research‑led pharmaceutical company" with a focus on innovation and accessibility.
• It operates 11 world‑class manufacturing facilities across four continents, supported by six cutting‑edge R&D centres, and has a commercial footprint in 80+ countries.
• Its portfolio spans branded, innovative, generics and consumer health products, with a focus on respiratory, dermatology, and oncology.
• The note adds that Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024.

Against that backdrop, another US respiratory approval is consistent with the company’s stated strategy and helps underpin the growth narrative that has supported the stock in recent months. The 4.2% intraday gain to Rs 2,341 suggests the market is assigning incremental value to this specific product launch within that larger framework.

Bottom line

The US FDA’s green light for Glenmark’s Fluticasone Propionate Nasal Spray gives the company an entry into a reference market that IQVIA pegs at about $295.2 million in annual sales, in a therapy area where Glenmark is already active. While the filing stops short of quantifying the earnings impact, the combination of a sizeable market opportunity and strategic fit with Glenmark’s US respiratory push appears to be driving the stock’s 4.2% move, with shares last changing hands at Rs 2,341.